A recent clinical trial of Dovitinib, a multikinase inhibitor with activity against FLT3/c-Kit, FGFR1/3 and VEGFR1-4 kinases, in patients with relapsed or refractory MM showed marginal efficacy in subjects with or without FGFR3 mutations [49]. The gene discussed is FLT3; the disease is Miyoshi myopathy.